STAR-K9E
Canine obesity · Caninized GLP-1 receptor agonist · once-weekly subcutaneous (target product profile)
Overview
- Species
- Dog
- Indication
- Canine obesity
- Target
- GLP-1 receptor
- Modality
- Caninized GLP-1 receptor agonist · once-weekly subcutaneous (target product profile)
- Current Stage
- Cell Line
- Route
- Lead pipeline · own approval
Why It Matters
A Category with No Approved GLP-1 Therapy
59% of US dogs are overweight or obese (APOP 2022 survey), yet no companion-animal GLP-1 receptor agonist has been approved. SmartGene caninizes a GLP-1 mechanism already validated in humans, with once-weekly dosing as the target product profile.
59%
US dogs overweight or obese (APOP 2022)
0
Approved companion-animal GLP-1 receptor agonists
Mechanism of action
Partnering
Co-Development Partners · Territory-Exclusive Licensees at Efficacy POC
Measured in vitro data is on file for binding, expression and canine-cell engagement. The full package is available under an executed CDA, and co-development is open from the current stage.
Every programme is in development and pre-approval. Product properties, including dosing interval and efficacy endpoints, are development targets and have not been established in vivo. Technical, market and development detail is available under an executed CDA.